Sector News

J&J to close plant, putting 400 jobs at risk

March 14, 2017
Life sciences

Johnson & Johnson is planning to close a surgical suture production plant, potentially putting 400 people out of work.

The shuttering of the Scottish facility will see J&J move production to larger sites in Texas, Brazil and Mexico to further its goal of cutting costs by $1 billion a year by 2018.

J&J revealed plans to lay off 3,000 people from its medical devices unit to lower costs at the start of last year, but held off on saying exactly where the ax would fall. Now, the 400 workers remaining at J&J’s Ethicon site in Scotland have learnt their employer sees the suture facility, which accounts for less than 6% of the company’s global capacity, as surplus to its needs.

“We have put forth these proposals in the interest of reducing complexity and increasing agility to better serve the needs of customers and patients in today’s evolving healthcare marketplace,” J&J said in a statement.

Locally, the action is happening against a backdrop of concerns multinational companies will leave the United Kingdom in response to Brexit. J&J’s proposal is motivated by other factors, but the timing is bad for a U.K. government keen to show the country remains attractive to global companies.

Currently, J&J is discussing the future of the plant and its employees with the Scottish and U.K. governments and local officials. Despite the government trying to find a way to keep Ethicon in Livingston, J&J looks set to shutter the site. The remaining question is whether J&J and the government can find a buyer for the facility and save some of the 400 jobs now under threat.

The proposed closure comes 14-years after J&J axed 850 jobs in Scotland as part of a restructuring that closed facilities in Edinburgh and Livingston and moved suture production to Puerto Rico and needle manufacturing to Brazil, Germany and the U.S.

More recently, J&J began this year by disclosing plans to lay off 80 people at its 1,100-person blood glucose meter operation in the Scottish city of Inverness. News of the cuts at the Inverness site broke at the same time as J&J revealed it is conducting a strategic review of its LifeScan blood glucose business and related diabetes brands. The review could see J&J parcel the brands up into a new business or sell them outright.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.